Goldman Sachs analyst David Roman lowered the firm’s price target on Insulet (PODD) to $365 from $388 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s New Omnipod M Study Targets the Untapped Type 2 Diabetes Pump Market
- Insulet’s Omnipod SmartAdjust 2.0 Trial Wraps Up: What Investors Should Watch Next
- Insulet price target lowered to $390 from $412 at Truist
- Insulet Revises Annual Incentive Plan for 2026
- Insulet price target raised to $450 from $432 at Canaccord